Table 3. Summary of the published... | American Society of Hematology

Table 3.

Summary of the published placebo-controlled trials of bisphosphonates in patients with multiple myeloma (MM).

	Belch³⁵ (1991)	Lahtinen³⁶ (1992)	Berenson³⁷ (1996)	McCloskey³⁸ (1998)	Menssen³⁹ (2002)
Etidronate: 5 mg/kg/d per os, 24 months per os
Clodronate: 2.4 mg/kg/d per os, 24 months (Lahtinen) and 1.6 d/day per os
Pamidronate: 90 mg IV, monthly 24 months
Ibandronate: 2 mg IV, monthly 12–24 months
^& Patients with no skeletal fracture at presentation
^# Patients with inhibition of bone resorption
Abbreviations: 0, no effect; +, beneficial effect; −, harmful effect; NA, not assessed.
No. evaluable patients	166	336	377	535	214
Bisphosphonates	Etidronate	Clodronate	Pamidronate	Clodronate	Ibandronate
Lytic bone lesions	0	+	0	NA	0
Pathologic fractures	0	0	+	+	0
Bone pain	0	0	+	+	0
Bone healing	0	NA	0	NA	Increase BMD
Hypercalcemia	0	0	+	+ (trend)	0
Survival	–	0	+ (trend)	+ (subset)^&	+ (subset)^#

	Belch³⁵ (1991)	Lahtinen³⁶ (1992)	Berenson³⁷ (1996)	McCloskey³⁸ (1998)	Menssen³⁹ (2002)
Etidronate: 5 mg/kg/d per os, 24 months per os
Clodronate: 2.4 mg/kg/d per os, 24 months (Lahtinen) and 1.6 d/day per os
Pamidronate: 90 mg IV, monthly 24 months
Ibandronate: 2 mg IV, monthly 12–24 months
^& Patients with no skeletal fracture at presentation
^# Patients with inhibition of bone resorption
Abbreviations: 0, no effect; +, beneficial effect; −, harmful effect; NA, not assessed.
No. evaluable patients	166	336	377	535	214
Bisphosphonates	Etidronate	Clodronate	Pamidronate	Clodronate	Ibandronate
Lytic bone lesions	0	+	0	NA	0
Pathologic fractures	0	0	+	+	0
Bone pain	0	0	+	+	0
Bone healing	0	NA	0	NA	Increase BMD
Hypercalcemia	0	0	+	+ (trend)	0
Survival	–	0	+ (trend)	+ (subset)^&	+ (subset)^#